AltMountain

Jones Hill Capital LP

New York, NY · CRD 339686
Hedge fund manager

Jones Hill Capital LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $642.4 million in regulatory assets under management. Its private funds, of all types, hold $230.3 million in gross assets. Over a longer period they returned an estimated +15.0% from Q2 2026 to Q2 2026, compared with +14.8% for the S&P 500, based on 13F filings.

Regulatory assets under management
$642.4 millionForm ADV Item 5.F
Gross assets of private funds
$230.3 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
8Form ADV Item 5.A
Registration
SEC-registered adviserCRD 339686
Latest Form ADV
05/06/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 1 quarters+15.0%Q2 2026 – Q2 2026
S&P 500+14.8%Same quarters, price only
13F holdings$470.4 million29 positions, 2026-06-30
$100$108$115Q2 202613F est. $115S&P 500 $115
QuarterEst. 13F returnS&P 500
Q2 2026+15.0%+14.8%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 33 share positions ($589,169,587) reported by Jones Hill Capital LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Biomarin Pharmaceutical Inc11.93%
  • Biocryst Pharmaceuticals Inc10.01%
  • Travere Therapeutics Inc9.59%
  • Indivior Pharmaceuticals Inc9.29%
  • Pharvaris N V5.32%
  • Celcuity Inc5.17%
  • Ionis Pharmaceuticals Inc4.55%
  • Supernus Pharmaceuticals4.40%
  • Nuvation Bio Inc4.26%
  • Vera Therapeutics Inc3.57%
StockValue% of 13F portfolioSharesShares vs prior quarter
Biomarin Pharmaceutical Inc$70,311,54011.93%1,171,859-18.14%
Biocryst Pharmaceuticals Inc$59,003,88910.01%7,083,300New
Travere Therapeutics Inc$56,503,2509.59%959,634New
Indivior Pharmaceuticals Inc$54,731,6579.29%1,526,685New
Pharvaris N V$31,327,8465.32%987,637+45.70%
Celcuity Inc$30,448,2885.17%382,901New
Ionis Pharmaceuticals Inc$26,782,2314.55%599,826New
Supernus Pharmaceuticals$25,896,5224.40%601,685New
Nuvation Bio Inc$25,127,1224.26%4,486,986New
Vera Therapeutics Inc$21,060,1193.57%652,218New
Trevi Therapeutics Inc$20,723,2743.52%1,447,156+8.06%
Bicara Therapeutics Inc$19,805,3763.36%1,064,233+19.23%
Relmada Therapeutics Inc$19,745,8583.35%5,237,628-4.47%
Abivax SA$14,116,0932.40%142,558New
Aclaris Therapeutics Inc$13,174,4642.24%2,504,651+42.35%
Insmed Inc$12,159,1062.06%106,528-12.95%
Neurocrine Biosciences Inc$11,833,1442.01%83,426New
Immunocore Hldgs PLC$11,639,7811.98%384,278-25.07%
Erasca Inc$8,944,3301.52%610,118New
Capricor Therapeutics Inc$8,452,2781.43%892,532+6.06%
Dianthus Therapeutics Inc$7,045,4971.20%80,017+40.13%
Neurogene Inc$6,056,4141.03%217,700New
Corbus Pharmaceuticals Hldgs$6,045,4391.03%886,428+35.63%
Tonix Pharmaceuticals Hldg C$5,490,8180.93%563,739-9.86%
Sagimet Biosciences Inc$4,965,5600.84%502,587New
Dyne Therapeutics Inc$4,847,4990.82%300,900New
Avalyn Pharmaceuticals Inc$3,610,9370.61%126,744New
Attovia Therapeutics Inc$3,124,5360.53%182,295New
Phathom Pharmaceuticals Inc$2,020,8590.34%276,830+71.43%
Lexeo Therapeutics Inc$2,006,8310.34%593,737New
Olema Pharmaceuticals Inc$1,783,2700.30%206,397-64.05%
Tenax Therapeutics Inc$230,8990.04%122,169New
Alvotech$154,8600.03%26,700New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 19 new positions, 15 sold out, 8 increased, 6 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions19
  • Increased8
  • Unchanged0
  • Reduced6
  • Sold out15

New positions

StockValueShares
Biocryst Pharmaceuticals Inc$59,003,8897,083,300
Travere Therapeutics Inc$56,503,250959,634
Indivior Pharmaceuticals Inc$54,731,6571,526,685
Celcuity Inc$30,448,288382,901
Ionis Pharmaceuticals Inc$26,782,231599,826
Supernus Pharmaceuticals$25,896,522601,685
Nuvation Bio Inc$25,127,1224,486,986
Vera Therapeutics Inc$21,060,119652,218
Abivax SA$14,116,093142,558
Neurocrine Biosciences Inc$11,833,14483,426
Erasca Inc$8,944,330610,118
Neurogene Inc$6,056,414217,700
Sagimet Biosciences Inc$4,965,560502,587
Dyne Therapeutics Inc$4,847,499300,900
Avalyn Pharmaceuticals Inc$3,610,937126,744
Attovia Therapeutics Inc$3,124,536182,295
Lexeo Therapeutics Inc$2,006,831593,737
Tenax Therapeutics Inc$230,899122,169
Alvotech$154,86026,700

Sold out

StockValue at Jun 30, 2026Shares held then
Gilead Sciences Inc$43,340,053343,043
Arcutis Biotherapeutics Inc$28,571,9601,089,701
Madrigal Pharmaceuticals Inc$28,214,03852,545
Xenon Pharmaceuticals Inc$22,206,444367,900
Ani Pharmaceuticals Inc$19,354,626233,808
Amylyx Pharmaceuticals Inc$16,057,282894,058
Nuvalent Inc$12,157,58798,442
Immunic Inc$8,296,941539,814
Oric Pharmaceuticals Inc$8,093,400747,313
Syndax Pharmaceuticals Inc$7,432,400340,000
Vir Biotechnology Inc$6,717,380659,213
Vertex Pharmaceuticals Inc$5,525,12811,123
Enliven Therapeutics Inc$2,529,88849,850
Structure Therapeutics Inc$2,177,23140,567
Achieve Life Science Inc$174,74326,760

Largest increases

StockChange in sharesChangeValue nowShares now
Pharvaris N V+309,758+45.70%$31,327,846987,637
Aclaris Therapeutics Inc+745,159+42.35%$13,174,4642,504,651
Bicara Therapeutics Inc+171,612+19.23%$19,805,3761,064,233
Dianthus Therapeutics Inc+22,917+40.13%$7,045,49780,017
Corbus Pharmaceuticals Hldgs+232,856+35.63%$6,045,439886,428
Trevi Therapeutics Inc+107,944+8.06%$20,723,2741,447,156
Phathom Pharmaceuticals Inc+115,344+71.43%$2,020,859276,830
Capricor Therapeutics Inc+51,030+6.06%$8,452,278892,532

Largest reductions

StockChange in sharesChangeValue nowShares now
Biomarin Pharmaceutical Inc-259,731-18.14%$70,311,5401,171,859
Immunocore Hldgs PLC-128,578-25.07%$11,639,781384,278
Olema Pharmaceuticals Inc-367,769-64.05%$1,783,270206,397
Insmed Inc-15,847-12.95%$12,159,106106,528
Relmada Therapeutics Inc-244,984-4.47%$19,745,8585,237,628
Tonix Pharmaceuticals Hldg C-61,689-9.86%$5,490,818563,739

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠